财务业绩 - 第二季度销售额40亿美元下降0.3%，有机增长1.5%[2][6] - 毛利率提升360个基点至59.1%，调整后毛利率提升410个基点至61.6%[8][9] - 营业利润率为3.9%，调整后营业利润率为22.8%[10][11] - 有效税率下降至10.8%，调整后有效税率为25.7%[13] - 净销售额为40亿美元，同比下降0.3%[41] - 毛利润为23.65亿美元，同比增长6.3%[41] - 净利润为5800万美元，同比下降86.5%[41] - 每股基本和稀释收益均为0.03美元[42] - 公司第二季度调整后营业收入为19.69亿美元，同比下降4.8%[87] - 公司第二季度调整后毛利率为61.6%，同比提升2.5个百分点[74] - 公司第二季度调整后营业利润率为22.8%，同比提升4.3个百分点[75] - 公司第二季度调整后EBITDA为9.83亿美元，EBITDA利润率为24.6%[76] - 公司第二季度调整后净利润为6.11亿美元，净利率为15.3%[76] - 公司本季度净销售额为78.63亿美元[98] - 毛利率为57.4%[99] - 经调整后的营业利润率为22.2%[100] - 经调整后的净利润率为15.4%[101] - 经调整后的EBITDA利润率为23.5%[101] - 公司本季度自由现金流为5亿美元[112] 业务表现 - 自我护理业务销售额为16.35亿美元，同比下降1.6%[45] - 皮肤健康和美容业务销售额为11.03亿美元，同比下降3.8%[45] - 基本健康业务销售额为12.62亿美元，同比增长4.9%[45] - 公司在北美、欧洲、亚太和拉美地区的销售收入分别为38.93亿、17.83亿、15.46亿和6.72亿美元[113] 非经常性项目 - 公司进行了5.1亿美元的减值计提[41] - 公司进行了4800万美元的重组费用[41] - 公司第二季度营业利润中包含5.78亿美元的减值费用[78] - 公司第二季度营业利润中包含1.46亿美元的重组费用和优化运营模式费用[78] - 公司第二季度营业利润中包含9.4亿美元的与分拆相关的费用[78] - 公司第二季度营业利润中包含2.3亿美元的与"延迟市场"相关的费用[78] - 公司第二季度营业利润中包含2000万美元的诉讼费用[78] 展望和指引 - 稀释每股收益0.03美元，调整后稀释每股收益0.32美元[3][14] - 确认2024财年销售额增长和调整后稀释每股收益的展望[16] - 重申2024财年销售额增长1.0%-3.0%(有机增长2.0%-4.0%)和调整后稀释每股收益1.10-1.20美元的展望[16] - 公司预计2024财年的有效税率将在25.5%-26.5%之间[108] - 公司预计2024财年的经调整每股收益将在0.60-0.68美元之间[109] 其他 - 生产效率提升推动加大品牌投资以促进未来增长[5] - 就Dr.Ci:Labo业务计提4.88亿美元的长期资产减值[15] - 公司本季度研发投入为2.05亿美元[114]

skhoward Introduction Consumer staples stocks and most other value stocks have performed quite well recently. However, shares of Kenvue Inc. (NYSE:KVUE), the former consumer health division of Johnson & Johnson (JNJ), don't seem to be getting any positive attention from Mr. Market. Although the stock is up 5% from its 52-week low of $17.7, it's worth noting that KVUE stock started trading as a separate company at nearly $27 last May. I have been following the company since the split-off became concrete, foc ...

Kenvue (KVUE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on August 6, 2024, might help the stock move higher if these key numbers are better than expectation ...

Irina Nedikova/iStock via Getty Images Foreword As a supplement to this article, please note that The Motley Fool, which sourced this latest list, and SureDividend both update their lists periodically. While most of this July collection of 53 Kings is too pricey to justify their skinny dividends, seven of the top-ten, by yield, and one more outside those ten, live up to the ideal. They offer annual dividends (from a $1K investment) exceeding their single share prices, and this month there are eight more ...

J Studios Overview Kenvue (NYSE:KVUE) was created as part of a spinoff from Johnson & Johnson's (JNJ) consumer health business. To get an idea of the products that shifted as part of this spinoff, we need to focus on the key word "consumer". Think about products like mouthwash, headache medicine, face creams, and first aid items. The business includes a portfolio of products that can be used every day, which means that it has a wide reach in terms of potential customer base. The spinoff from JNJ was a r ...

It’s a great time to be looking at healthcare stocks to buy now.According to research from BlackRock, U.S. healthcare stocks have outperformed the overall stock market by an average of 10% over the past seven recessions. Given high interest rates, inflation and the possibility of an economic slowdown in coming months, it could be a great time for defensive investment categories such as healthcare.More broadly, the sector should enjoy several positive factors in coming years. For one, there is demographics. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-41697 Kenvue Inc. (Exact name of registrant as specified in its charter) Delaware 88-1032011 (State or other jurisdiction of (I.R.S. Emplo ...

Kenvue Inc. (NYSE:KVUE) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Tina Romani - Investor Relations Thibaut Mongon - Chief Executive Officer Paul Ruh - Chief Financial Officer Conference Call Participants Andrea Teixeira - J.P. Morgan Bonnie Herzog - Goldman Sachs Stephen Powers - Deutsche Bank Nik Modi - RBC Capital Markets Anna Lizzul - Bank of America Securities Filippo Falorni - Citigroup Korinne Wolfmeyer - Piper Sandler Operator Hello and welcome to Kenvue First Quart ...

Kenvue Reports First Quarter 2024 Results Q1’24: Net Sales Increased 1.1% to $3.9 Billion with Organic Growth1 of 1.9% Q1’24: Diluted Earnings per Share of $0.15; Adjusted Diluted Earnings per Share1 of $0.28 Reaffirms Fiscal Year 2024 Outlook SKILLMAN, N.J. May 7, 2024 – Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal first quarter ended March 31, 2024. “We entered 2024 with clear strategic priorities to reach more consumers, reinvent our ways of working to invest more ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-41697 Kenvue Inc. (Exact name of registrant as specified in its charter) Delaware 88-1032011 (State or other jurisdiction of (I.R.S. Employer i ...